Evidence map›Paper›PMID 37734923›Full record

ArticleEpilepsia2023

GRIN1 variants associated with neurodevelopmental disorders reveal channel gating pathomechanisms.

Lotten Ragnarsson, Zihan Zhang, Sooraj S Das, Poanna Tran, Åsa Andersson, Vincent des Portes, Cecilia Desmettre Altuzarra, Ganaelle Remerand, Audrey Labalme, Nicolas Chatron and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Epilepsia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Transcriptomic Profiling of Zebrafish Mutant forInternational journal of molecular sciences · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Lotten RagnarssonInstitute for Molecular Bioscience, University of Queensland, St. Lucia, Queensland, Australia.
Zihan ZhangInstitute for Molecular Bioscience, University of Queensland, St. Lucia, Queensland, Australia.
Sooraj S DasClem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia.
Poanna TranInstitute for Molecular Bioscience, University of Queensland, St. Lucia, Queensland, Australia.
Åsa AnderssonInstitute for Molecular Bioscience, University of Queensland, St. Lucia, Queensland, Australia.
Vincent des PortesNeuropaediatrics Department, Femme Mère Enfant Hospital, Lyon, France.
Cecilia Desmettre AltuzarraDepartment of Pediatrics, Centre Hospitalier Universitaire (CHU), Besançon, France.
Ganaelle RemerandDepartment of Neonatology, Estaing Hospital, Centre Hospitalier Universitaire (CHU), Clermont-Ferrand, France.
Audrey LabalmeService de Génétique, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.
Nicolas ChatronService de Génétique, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.
Damien SanlavilleService de Génétique, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.
Gaetan LescaService de Génétique, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.ORCID 0000-0001-7691-9492
Victor AnggonoClem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia.
Irina VetterInstitute for Molecular Bioscience, University of Queensland, St. Lucia, Queensland, Australia.
Angelo KeramidasInstitute for Molecular Bioscience, University of Queensland, St. Lucia, Queensland, Australia.ORCID 0000-0003-2846-052X
The University of Queensland · AUHospices Civils de Lyon · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRUniversité Claude Bernard Lyon 1 · FR

Funding

Australian Research Council DP190101390National Health and Medical Research Council GNT1156673
6 · The paper itself

Abstract

objectiveN-methyl-d-aspartate (NMDA) receptors are expressed at synaptic sites, where they mediate fast excitatory neurotransmission. NMDA receptors are critical to brain development and cognitive function. Natural variants to the GRIN1 gene, which encodes the obligatory GluN1 subunit of the NMDA receptor, are associated with severe neurological disorders that include epilepsy, intellectual disability, and developmental delay. Here, we investigated the pathogenicity of three missense variants to the GRIN1 gene, p. Ile148Val (GluN1-3b[I481V]), p.Ala666Ser (GluN1-3b[A666S]), and p.Tyr668His (GluN1-3b[Y668H]).

methodsWild-type and variant-containing NMDA receptors were expressed in HEK293 cells and primary hippocampal neurons. Patch-clamp electrophysiology and pharmacology were used to profile the functional properties of the receptors. Receptor surface expression was evaluated using fluorescently tagged receptors and microscopy.

resultsOur data demonstrate that the GluN1(I481V) variant is inhibited by the open pore blockers ketamine and memantine with reduce potency but otherwise has little effect on receptor function. By contrast, the other two variants exhibit gain-of-function molecular phenotypes. Glycine sensitivity was enhanced in receptors containing the GluN1(A666S) variant and the potency of pore block by memantine and ketamine was reduced, whereas that for MK-801 was increased. The most pronounced functional deficits, however, were found in receptors containing the GluN1(Y668H) variant. GluN1(Y668H)/2A receptors showed impaired surface expression, were more sensitive to glycine and glutamate by an order of magnitude, and exhibited impaired block by extracellular magnesium ions, memantine, ketamine, and MK-801. These variant receptors were also activated by either glutamate or glycine alone. Single-receptor recordings revealed that this receptor variant opened to several conductance levels and activated more frequently than wild-type GluN1/2A receptors. SIGNIFICANCE: Our study reveals a critical functional locus of the receptor (GluN1[Y668]) that couples receptor gating to ion channel conductance, which when mutated may be associated with neurological disorder.

Indexed as

KetamineNeurodevelopmental DisordersDizocilpine MaleateGlutamatesGlycineHEK293 CellsHumansMemantineNerve Tissue ProteinsReceptors, N-Methyl-D-AspartateDizocilpine MaleateGlutamatesGlycineGRIN1 protein, humanKetamineMemantineNerve Tissue ProteinsReceptors, N-Methyl-D-Aspartatedevelopmental delayepilepsyNMDA receptors

Identifiers

PMID37734923
PMCPMC10952597
OpenAlexW4386913403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.